SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
Valuation | |
---|---|
Market Cap ($M) | 350.45 |
Enterprise Value ($M) | 325.03 |
Book Value ($M) | 104.31 |
Book Value / Share | 1.85 |
Price / Book | 3.36 |
NCAV ($M) | 80.59 |
NCAV / Share | 1.43 |
Price / NCAV | 4.35 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.62 |
Return on Assets (ROA) | -0.67 |
Return on Equity (ROE) | -0.97 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 7.05 |
Current Ratio | 7.05 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 118.81 |
Assets | 142.52 |
Liabilities | 38.22 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -86.46 |
Net Income | -82.44 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -66.72 |
Cash from Investing | 16.35 |
Cash from Financing | 71.93 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | T. Rowe Price Investment Management, Inc. | 18.90 | 59.68 | |
13D/A | New Enterprise Associates 16, L.P. | 8.10 | 31.84 | |
13D/A | Ra Capital Management, L.p. | 4.95 | 7.65 | |
13G/A | Bb Biotech Ag | 16.50 | 58.39 | |
13D/A | Versant Venture Capital VI, L.P. | 8.40 | 0.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
33,759 | 188,918 | 17.87 | |
33,076 | 206,454 | 16.02 | |
24,718 | 176,422 | 14.01 | |
52,134 | 280,478 | 18.59 | |
52,108 | 194,528 | 26.79 | |
(click for more detail) |
Similar Companies | |
---|---|
AVXL – Anavex Life Sciences Corp. | BBIO – BridgeBio Pharma, Inc. |
BCRX – BioCryst Pharmaceuticals, Inc. | BEAM – Beam Therapeutics Inc. |
BIIB – Biogen Inc. |
Financial data and stock pages provided by
Fintel.io